RxDoctor Payments Data

David Rodriguez, MD

Internal Medicine · Atlanta, GANPI 1376656447

Payments from drug & device makers

$1,376in general payments, 2019–2025

Across 75 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$274
  • Amgen$248
  • Novo Nordisk$129
  • Otsuka America Pharmaceutical, Inc.$106
  • Exact Sciences$74
  • Kowa Pharmaceuticals America, Inc.$65
  • plus $480 from 17 others

What the payments were for

  • Food & beverage$1,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,376 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$191,234
Medicare patients
275
Services billed
8,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$113,857
OzempicSemaglutide111$112,242
JardianceEmpagliflozin78$83,209
XareltoRivaroxaban55$57,777
EliquisApixaban68$52,575
Dupixent PenDupilumab12$44,904
MyrbetriqMirabegron54$41,539
RybelsusSemaglutide18$37,515
RexultiBrexpiprazole14$19,960
FarxigaDapagliflozin Propanediol26$15,570
Repatha SureclickEvolocumab17$9,448
EntrestoSacubitril/Valsartan14$9,090
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,171
GemtesaVibegron16$7,875
Rivastigmine26$6,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$129$149,757129 claims
Lilly USA, LLCMounjaro$18$113,857107 claims
PfizerEliquis, Paxlovid$23$56,863109 claims
AstraZenecaFarxiga, Breztri Aerosphere$30$23,74139 claims
Otsuka America Pharmaceutical, Inc.Rexulti$106$19,96014 claims
NovartisEntresto$19$9,09014 claims
AbbVieSynthroid$274$3,15043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →